Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.

被引：0

作者：

Cobb, Patrick Wayne

Zhou, Heng

Nahar, Akash

Marinello, Patricia

机构：

[1] St Vincent Healthcare Canc Ctr Montana, Billings, MT USA

[2] Merck & Co Inc, Kenilworth, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7592

引用

页数：1

共 50 条

[21] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
de Vos, S
Fernando, D
Schenkein, DP
Rosen, PJ
BLOOD, 2005, 106 (11) : 267B - 267B
[22] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Goy, Andre
Ramchandren, Radhakrishnan
Ghosh, Nilanjan
Munoz, Javier
Morgan, David S.
Dang, Nam H.
Knapp, Mark
Delioukina, Maria
Kingsley, Edwin C.
Anh Tran
Ping, Jerry
Beaupre, Darrin M.
Neuenburg, Jutta K.
Ruan, Jia
BLOOD, 2016, 128 (22)
[23] Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma
Hatton, C. S. R.
Peniket, A.
Tusold, A.
Collins, G. P.
Joyner, M.
Lee, R.
Mouncey, P.
Smith, P.
Lee, S-M
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 13 - 13
[24] A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ward, Jeffrey P.
Thein, Jessica
Luo, Jingqin
Wagner-Johnston, Nina D.
Cashen, Amanda F.
Fehniger, Todd A.
Bartlett, Nancy L.
BLOOD, 2015, 126 (23)
[25] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
Lin, Ningjing
Sun, Xiuhua
Zhou, Hui
Zou, Liqun
Zhou, Keshu
Liu, Lihong
Yang, Haiyan
Hu, Kai
Cai, Qingqing
Liu, Yao
Jin, Jie
Zhang, Liling
Li, Wenyu
Guo, Ye
Yang, Wei
Luo, Feng
Wang, Zhenguang
Zhu, Rong
Yang, Lei
Song, Dan
Song, Yuqin
Zhu, Jun
HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
[26] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
Matasar, M.
Herrera, A. F.
Kamdar, M.
Mehta, A.
Assouline, S.
Fleury, I.
Kim, T. M.
Kim, W. S.
Bosch, F.
Radford, J.
Flowers, C. R.
Bu, L.
Hong, W. -J.
Sehn, L. H.
HAEMATOLOGICA, 2017, 102 : 173 - 173
[27] Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study
Paskiewicz-Kozik, Ewa
Glimelius, Ingrid
Moreira, Claudia
Garrido, Marcelo
Ernst, Daniel
Jurczak, Wojciech
Merryman, Reid
Kim, Won Seog
Ozcan, Muhit
Santoro, Armando
Sawalha, Yazeed
Berkovits, Alejandro
Ren, Yixin
Ogbu, Uzor
Yusuf, Rushdia
Zinzani, Pier Luigi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S483 - S484
[28] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Gritti, Giuseppe
Marlton, Paula
Phillips, Tycel J.
Arthur, Christopher
Bannerji, Rajat
Corradini, Paolo
Johnston, Anna
Seymour, John F.
Yuen, Sam
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Flowers, Christopher
BLOOD, 2020, 136
[29] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Kayoko Murayama
Toru Kiguchi
Koji Izutsu
Yoshihiro Kameoka
Michihiro Hidaka
Harumi Kato
Shinya Rai
Junya Kuroda
Kenichi Ishizawa
Satoshi Ichikawa
Kiyoshi Ando
Michinori Ogura
Koji Fukushima
Yasuhito Terui
Annals of Hematology, 2022, 101 : 979 - 989
[30] Single Agent Ofatumumab In Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results From a Phase II Open Label Study
Jasielec, Jagoda
Peace, David
Edwards, Sarah
Tolzien, Kathy
Smith, Sonali M.
Nabhan, Chadi
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →